ABT vs WLYB · P/E 25, rev $44.33B vs P/E 15, rev $1.68B
Abbott Laboratories (ABT) versus John Wiley & Sons B (WLYB) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
John Wiley & Sons B (WLYB) is a publishing company listed on NYSE.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported WLYB revenue for 2026-04-30 was $1.68B. Net income was $221.6M. Revenue was down 0.1% from 2025-04-30 to 2026-04-30. WLYB currently screens at market cap $2.26B and trailing P/E 15.4.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. WLYB currently screens at market cap $2.26B and trailing P/E 15.4.
Not investment advice. Open the ABT and WLYB stock pages for the full models.
Not investment advice.